miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference. Mr. Salman will introduce miR Scientific`s proprietary, highly accurate, award winning sncRNA interrogation platform, highlight its recent FDA breakthrough designation and present miR`s commercial launch plans for its non-invasive liquid biopsy urine test. Mr. Salman will also introduce clinical collaboration roadmaps, the company`s product pipeline and global growth initiatives.

The presentation is scheduled for Wednesday, January 13th, 2021 and will begin at 3:10pm EDT.  A live webcast for conference participants will be available here.